A prospective, longitudinal ergospirometry trial to study altered objective exertion tolerance in relapsing-remitting multiple sclerosis patients treated with fingolimod

Trial Profile

A prospective, longitudinal ergospirometry trial to study altered objective exertion tolerance in relapsing-remitting multiple sclerosis patients treated with fingolimod

Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2016

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 New trial record
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top